Drug intelligence / Profile preview

AJN005

Development stage: Preclinical
Lead developer: AltrixBio
Modality: Small Molecules
Administration: Oral

Overview

AJN005 is a preclinical-stage small molecule asset developed by AltrixBio for targeted drug delivery. The technology is designed for oral administration and enables the location-specific delivery of therapeutic drug payloads within the gastrointestinal (GI) tract. By facilitating site-specific release, AJN005 aims to optimize the therapeutic efficacy and safety profile of various drug payloads by ensuring they reach their intended site of action within the GI system while potentially minimizing systemic exposure or degradation in non-target regions.

Beyond the preview

Go deeper on AJN005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJN005.

Explore the full profile